Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1362 of 1,362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pump Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Lofexidine ADME & Mass Balance in Volunteers

NCT01310296
View directory record Official record
Conditions
Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product
Interventions
Lofexidine hydrochloride
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

Single Hormone Closed Loop Study With PDT Sensor

NCT03528174
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Artificial Pancreas Control system (APC), Pacific Diabetes Technologies CGM Insulin Infusion system
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 31, 2026, 1:33 PM EDT
Withdrawn Not applicable Interventional

A Performance Evaluation of the Enlite 3 Sensor

NCT02649010
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Enlite 3 Sensor
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
14 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Walnut Creek, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 31, 2026, 1:33 PM EDT
Recruiting No phase listed Observational

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

NCT07102160
View directory record Official record
Conditions
Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Interventions
Aspiration thrombectomy system
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Indianapolis, Indiana • Edgewood, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

NCT02930824
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 100 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Phase 1 Interventional

Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System

NCT01271023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control-to-Range Automated Insulin Management System
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 31, 2026, 1:33 PM EDT
Not listed Phase 4 Interventional

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

NCT04414579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Faster Insulin Aspart (Fiasp®)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

NCT02708355
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Insulin Management System
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 8 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 31, 2026, 1:33 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine for Pain Management

NCT02542956
View directory record Official record
Conditions
Pain
Interventions
Exparel, Marcaine
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

NCT05564637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
Interventions
Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 31, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

NCT03681951
View directory record Official record
Conditions
Neoplasms, Pancreatic
Interventions
GSK3145095, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

The Insulin-Only Bionic Pancreas Pivotal Trial

NCT04200313
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
Bionic Pancreas (BP) with Aspart or Lispro, Bionic Pancreas with Fiasp (BPFiasp), Usual Care (UC), BP Guidance Insulin Dosing
Combination Product · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
16
States / cities
Orange, California • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 31, 2026, 1:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

NCT05543746
View directory record Official record
Conditions
Postpartum Depression
Interventions
Brexanolone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 31, 2026, 1:33 PM EDT
Completed Phase 1 Interventional

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

NCT00493961
View directory record Official record
Conditions
Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 31, 2026, 1:33 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

NCT03737604
View directory record Official record
Conditions
Transplant;Failure,Kidney, Pain, Postoperative
Interventions
Ropivacaine Continuous Infusion Catheter, Single Dose Liposomal Bupivicaine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 1:33 PM EDT